KR101125460B1 - 에피루비신 염산염의 신규한 결정형 - Google Patents

에피루비신 염산염의 신규한 결정형 Download PDF

Info

Publication number
KR101125460B1
KR101125460B1 KR1020100026484A KR20100026484A KR101125460B1 KR 101125460 B1 KR101125460 B1 KR 101125460B1 KR 1020100026484 A KR1020100026484 A KR 1020100026484A KR 20100026484 A KR20100026484 A KR 20100026484A KR 101125460 B1 KR101125460 B1 KR 101125460B1
Authority
KR
South Korea
Prior art keywords
epirubicin hydrochloride
crystalline form
ray powder
present
powder diffraction
Prior art date
Application number
KR1020100026484A
Other languages
English (en)
Korean (ko)
Other versions
KR20110107237A (ko
Inventor
김문성
김순회
최준호
성시영
임홍규
차대원
손병화
류기문
Original Assignee
동아제약주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44673730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101125460(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 동아제약주식회사 filed Critical 동아제약주식회사
Priority to KR1020100026484A priority Critical patent/KR101125460B1/ko
Priority to PCT/KR2011/001706 priority patent/WO2011118929A2/fr
Priority to TW100109850A priority patent/TW201143777A/zh
Publication of KR20110107237A publication Critical patent/KR20110107237A/ko
Application granted granted Critical
Publication of KR101125460B1 publication Critical patent/KR101125460B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1020100026484A 2010-03-24 2010-03-24 에피루비신 염산염의 신규한 결정형 KR101125460B1 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR1020100026484A KR101125460B1 (ko) 2010-03-24 2010-03-24 에피루비신 염산염의 신규한 결정형
PCT/KR2011/001706 WO2011118929A2 (fr) 2010-03-24 2011-03-11 Nouvelles formes cristallines de chlorhydrate d'épirubicine
TW100109850A TW201143777A (en) 2010-03-24 2011-03-23 Novel crystal forms of Epirubicin hydrochloride

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020100026484A KR101125460B1 (ko) 2010-03-24 2010-03-24 에피루비신 염산염의 신규한 결정형

Publications (2)

Publication Number Publication Date
KR20110107237A KR20110107237A (ko) 2011-09-30
KR101125460B1 true KR101125460B1 (ko) 2012-03-28

Family

ID=44673730

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020100026484A KR101125460B1 (ko) 2010-03-24 2010-03-24 에피루비신 염산염의 신규한 결정형

Country Status (3)

Country Link
KR (1) KR101125460B1 (fr)
TW (1) TW201143777A (fr)
WO (1) WO2011118929A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011103751A1 (de) * 2011-05-31 2012-12-06 Heraeus Precious Metals Gmbh & Co. Kg Kristallisierung von Epirubicinhydrochlorid
EP2778171A1 (fr) * 2013-03-15 2014-09-17 Synbias Pharma Ltd. Monohydrate cristallin d'hydrochlorure d'épirubicine
CN109384822B (zh) * 2017-08-11 2021-08-03 鲁南制药集团股份有限公司 一种盐酸表柔比星晶型及其制备方法
KR102275454B1 (ko) 2020-05-07 2021-07-09 건국대학교 산학협력단 전능성 줄기세포로부터 중간엽 줄기세포를 분화시키는 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874550A (en) 1996-12-16 1999-02-23 Pharmachemie B.V. Process for preparing epirubicin or acid addition salts thereof from daunorubicin
US20060063726A1 (en) 2003-07-02 2006-03-23 Victor Matvienko Thermally stable crystalline epirubicin hydrochloride and method of making the same
US20090099346A1 (en) 2003-07-02 2009-04-16 Victor Matvienko Thermally stable crystalline epirubicin hydrochloride

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4345068A (en) * 1979-11-22 1982-08-17 Farmitalia Carlo Erba S.P.A. Process for the preparation of 4'-epidaunorubicin, 3',4'-diepidaunorubicin, their doxorubicin analogs, and intermediates used in said process

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874550A (en) 1996-12-16 1999-02-23 Pharmachemie B.V. Process for preparing epirubicin or acid addition salts thereof from daunorubicin
US20060063726A1 (en) 2003-07-02 2006-03-23 Victor Matvienko Thermally stable crystalline epirubicin hydrochloride and method of making the same
US20090099346A1 (en) 2003-07-02 2009-04-16 Victor Matvienko Thermally stable crystalline epirubicin hydrochloride

Also Published As

Publication number Publication date
WO2011118929A2 (fr) 2011-09-29
KR20110107237A (ko) 2011-09-30
WO2011118929A3 (fr) 2012-01-05
TW201143777A (en) 2011-12-16

Similar Documents

Publication Publication Date Title
AU2011213431B2 (en) Polymorphs of dasatinib, preparation methods and pharmaceutical compositions thereof
EP3470400A1 (fr) Forme cristalline de l'ozanimod, forme cristalline de son hydrochloride et son procédé de préparation
CZ283181B6 (cs) Farmaceutická činidla
US10882825B2 (en) Non-solvated crystal, preparation method and application thereof
EP3466958B1 (fr) Nouvelles formes cristallines d'un médicament inhibiteur des cotransporteurs de sodium-glucose, leur procédé de préparation et leur utilisation
EP2861589A2 (fr) Cristaux à plusieurs composants comprenant du dasatinib et des agents de formation de cocristaux choisis
KR101125460B1 (ko) 에피루비신 염산염의 신규한 결정형
CA2950485A1 (fr) Cristaux multi-composants de dasatinib avec du menthol ou de la vanilline
CN112047892A (zh) 一种吉非替尼与3-羟基苯甲酸共晶体
KR102572035B1 (ko) 무정형 형태의 빌란테롤 트리페나테이트 및 이의 제조방법
CN112047893A (zh) 吉非替尼与水杨酸共晶体
TW201900634A (zh) (s)-[2-氯-4-氟-5-(7-嗎啉-4-基喹唑啉-4-基)苯基]-(6-甲氧基-嗒𠯤-3-基)-甲醇之固體型式
JP7303821B2 (ja) ピリミジニルアミノ－ピラゾール化合物の多形体及び固体形態、ならびに製造方法
EP3135666B1 (fr) Forme cristalline iii du (s)-oxiracétam, son procédé de préparation, et application
EP3992192A1 (fr) Formes de sel dominantes de dérivés de pyrimidine et leurs formes cristallines
KR20100019979A (ko) 의약조성물
EP4313945B1 (fr) Sel de bromhydrate cristallin de 5-meo-dmt
AU2018208913A1 (en) Crystal form of GFT-505 and preparation method and use thereof
ES2716420T3 (es) Clorhidrato de eliglustat cristalino
ES2634666T3 (es) Polimorfo de 3-(dihidroisoindolinon-2-il sustituido)-2,6-dioxopiperidina, y composiciones farmacéuticas de la misma
EP3898596B1 (fr) Composé pharmaceutique, son procédé de fabrication et son utilisation en tant qu'agent thérapeutique
JP2021102642A (ja) 結晶性β−ラクタマーゼ阻害剤
CN112225732B (zh) 一种盐酸哌罗匹隆水合物晶型及其制备方法
EP3812384B1 (fr) Maléate d'un composé de benzothiophène, forme cristalline correspondante et utilisation associée
EP4273144A1 (fr) Forme cristalline de l'entrectinib et procédé de préparation associé

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
J204 Invalidation trial for patent
J301 Trial decision

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20120628

Effective date: 20130123

LAPS Lapse due to unpaid annual fee